Total and ultrafilterable platinum (Pt) disposition was investigated during 49 courses of chemotherapy in 13 patients with germ cell tumor treated with cisplatin (DDP), 20 mg/m2/day on 5 consecutive days. The following pharmacokinetic parameters were analyzed: distribution (t½α) and elimination (t½β) half-lives, total body clearance (ClT), renal clearance (ClR), and areas under the concentration versus time curve (AUCs). Blood samples were collected immediately before and after DDP infusion (Day 1 through Day 5); in addition, on Day 5, samples were collected at 0.25, 0.5, 1, 8, 24, and 48 h after DDP infusion. Urine was collected during each day of treatment and up to 48 h after the last DDP dose. During each chemotherapy cycle plasma level...
Cisplatin is the first choice treatment in mediastinal germ cell tumors. However, concerns regarding...
The use of cisplatin for the treatment of metastatic testicular cancer is a medical historical landm...
International audienceBACKGROUND: Ovarian cancer is the leading cause of gynaecological cancer-relat...
The pharmacokinetics of cisplatin were investigated in 14 patients, aged 10 months through 13 years ...
The treatment of elderly patients with cancer may be difficult because of the narrow therapeutic ind...
The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function o...
The pharmacokinetics of total platinum (Pt) in plasma and cisplatin (CDDP)-DNA adducts in different ...
International audienceOvarian cancer is the leading cause of gynecological cancer-related death in W...
The feasibility of monitoring cisplatin chemotherapy by measuring plati num (Pt) concentrations in b...
Pharmacokinetic (PK) studies of oxaliplatin, using a dose regimen of 85mg/m(2) are lacking. A PK mod...
Pharmacokinetic (PK) studies of oxaliplatin, using a dose regimen of 85 mg/m, are lacking. A PK mode...
Platmum levels have been determined in 145 samples from 24 tissues and 7 types of tumours from patie...
Methodological tools for studies of the cytostatic agen cisplatin (CDDP) were explored and applied t...
Cis-diamminedichloroplatinum (II) (Cis-DDP) is a relatively new chemotherapeutic agent used in the t...
Cisplatin is the first choice treatment in mediastinal germ cell tumors. However, concerns regarding...
The use of cisplatin for the treatment of metastatic testicular cancer is a medical historical landm...
International audienceBACKGROUND: Ovarian cancer is the leading cause of gynaecological cancer-relat...
The pharmacokinetics of cisplatin were investigated in 14 patients, aged 10 months through 13 years ...
The treatment of elderly patients with cancer may be difficult because of the narrow therapeutic ind...
The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function o...
The pharmacokinetics of total platinum (Pt) in plasma and cisplatin (CDDP)-DNA adducts in different ...
International audienceOvarian cancer is the leading cause of gynecological cancer-related death in W...
The feasibility of monitoring cisplatin chemotherapy by measuring plati num (Pt) concentrations in b...
Pharmacokinetic (PK) studies of oxaliplatin, using a dose regimen of 85mg/m(2) are lacking. A PK mod...
Pharmacokinetic (PK) studies of oxaliplatin, using a dose regimen of 85 mg/m, are lacking. A PK mode...
Platmum levels have been determined in 145 samples from 24 tissues and 7 types of tumours from patie...
Methodological tools for studies of the cytostatic agen cisplatin (CDDP) were explored and applied t...
Cis-diamminedichloroplatinum (II) (Cis-DDP) is a relatively new chemotherapeutic agent used in the t...
Cisplatin is the first choice treatment in mediastinal germ cell tumors. However, concerns regarding...
The use of cisplatin for the treatment of metastatic testicular cancer is a medical historical landm...
International audienceBACKGROUND: Ovarian cancer is the leading cause of gynaecological cancer-relat...